Description

EC1167 hydrochloride is the linker for EC1169. EC1169 is prostate-specific membrane antigen targeting-tubulysin conjugate. EC1169 hydrochloride has the potential to treat recurrent metastatic, castration-resistant prostate cancer (MCRPC)[1].–20°C (Powder, protect from light, stored under nitrogen)-Applications-Cancer-programmed cell death-Formula-C33H46ClN7O17S-Citation–References-[1]Leamon CP, et al. Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate. Bioconjug Chem. 2019 Jun 19;30(6):1805-1813.-CASNumber–MolecularWeight-880.27-Compound Purity-98.04-SMILES-SC[C@@H](C(O)=O)NC([C@H](CC(O)=O)NC([C@H](CC(O)=O)NC(CC1=CC=C(CNC(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)C=C1)=O)=O)=O.Cl-Research_Area-Cancer-Solubility-DMSO : 125 mg/mL (ultrasonic)-Target-ADC Linker-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related